Research programme: respiratory syncytial virus infections therapy - Vaxart
Alternative Names: BTA-C286; BTA-RSV2; BTA-RSV3Latest Information Update: 28 Jul 2018
At a glance
- Originator Biomolecular Research Institute; Biota Holdings
- Developer Aviragen Therapeutics; Vaxart
- Class Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Australia (IV)
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Australia (PO)